MedTrace Logo

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

NCT03297593 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-06-06

No results posted yet for this study

Summary

Immunotherapy with checkpoint inhibitors that target PD-1 and CTLA-4 have shown activity in mRCC. However, the optimal schedule of the combination therapy has yet to be defined.

The objective of the trial is to determine the efficacy of combination immunotherapy of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma.

The expansion phase shall address the role of ipilimumab in case of clinically insignificant progression.

Conditions

Interventions

DRUG

nivolumab

240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter

DRUG

ipilimumab

After 2 weeks 1mg/kg every 6 weeks

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Frank Stenner, Prof · Universitätsspital Basel

  • Heinz Läubli, MD · Universitätsspital Basel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-13
Primary Completion
2019-07-01
Completion
2025-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03297593 on ClinicalTrials.gov